Mainz Biomed BV (NASDAQ:MYNZ) — Market Cap & Net Worth
Market Cap & Net Worth: Mainz Biomed BV (MYNZ)
Mainz Biomed BV (NASDAQ:MYNZ) has a market capitalization of $4.11 Million ($4.11 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28714 globally and #5639 in its home market, demonstrating a -16.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mainz Biomed BV's stock price $0.76 by its total outstanding shares 5412853 (5.41 Million). Analyse MYNZ cash flow conversion to see how efficiently the company converts income to cash.
Mainz Biomed BV Market Cap History: 2021 to 2026
Mainz Biomed BV's market capitalization history from 2021 to 2026. Data shows change from $56.24 Million to $4.11 Million (-55.80% CAGR).
Index Memberships
Mainz Biomed BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #851 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2724 of 3165 |
Weight: Mainz Biomed BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mainz Biomed BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mainz Biomed BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
26.16x
Mainz Biomed BV's market cap is 26.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $56.24 Million | $577.35K | -$11.69 Million | 97.41x | N/A |
| 2022 | $38.43 Million | $529.88K | -$26.45 Million | 72.53x | N/A |
| 2023 | $6.28 Million | $895.48K | -$26.30 Million | 7.01x | N/A |
| 2024 | $23.38 Million | $893.99K | -$21.65 Million | 26.16x | N/A |
Competitor Companies of MYNZ by Market Capitalization
Companies near Mainz Biomed BV in the global market cap rankings as of May 2, 2026.
Key companies related to Mainz Biomed BV by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Mainz Biomed BV Historical Marketcap From 2021 to 2026
Between 2021 and today, Mainz Biomed BV's market cap moved from $56.24 Million to $ 4.11 Million, with a yearly change of -55.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.11 Million | -32.29% |
| 2025 | $6.06 Million | -74.07% |
| 2024 | $23.38 Million | +272.41% |
| 2023 | $6.28 Million | -83.66% |
| 2022 | $38.43 Million | -31.67% |
| 2021 | $56.24 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Mainz Biomed BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.11 Million USD |
| MoneyControl | $4.11 Million USD |
| MarketWatch | $4.11 Million USD |
| marketcap.company | $4.11 Million USD |
| Reuters | $4.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more